FOLD - Amicus closes up 5% as it expects approval of Pompe disease therapy
2023-09-27 16:35:27 ET
More on Amicus Therapeutics
- Amicus: Holding Until AT-GAA U.S. Approval
- Amicus Therapeutics: U.K. Approval Expands Global Reach
- Amicus announces U.K. approval and launch of Pompe disease therapy
- Amicus Therapeutics reports mixed Q2 earnings; updates FY23 outlook
For further details see:
Amicus closes up 5% as it expects approval of Pompe disease therapy